LFAS
CLDX icon

Level Four Advisory Services’s Celldex Therapeutics CLDX Stock Holding History

Level Four Advisory Services’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,605
Closed -$357K – 476
2017
Q1 		$357K Buy
+6,605
New +$344K 0.04% 380

Other funds holding CLDX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Level Four Advisory Services's CLDX Position: Q2 2017 in Review

Level Four Advisory Services sold out of Celldex Therapeutics (CLDX) in Q2 2017, closing a stake of 6,605 shares — an estimated $357K sold.

Level Four Advisory Services first reported a position in CLDX in Q1 2017 and held it in 1 quarter. The position peaked at $357K in Q1 2017. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

  • Level Four Advisory Services reported no remaining Celldex Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Level Four Advisory Services sold 6,605 Celldex Therapeutics shares in Q2 2017, an estimated $357K.
  • Level Four Advisory Services first reported a position in Celldex Therapeutics in Q1 2017 and held it in 1 quarter.
  • Level Four Advisory Services's Celldex Therapeutics position peaked at $357K in Q1 2017.
  • 130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on Level Four Advisory Services's 13F filing for Q2 2017, filed 12 Jul 2017.